The media, as well as the medical community's fixation with folate (folic acid is the synthetic form we are more familiar with) has been well documented. It is rare that a public health success story (in this case of reducing neural tube defects around the globe through fortification) has been so scrutinized. Researchers have a right to be cautious about folate because it is a nutrient that promotes cell reproduction, which in most cases is a good thing unless the cells producing rapidly are cancer cells. Here is the latest on the wonderful nutrient, folate:
Canada's Population Study
A study in Canadian Medical Association Journal is the first of its kind in more than three decades to examine the folate status of Canadians. Red blood cell folate concentrations were examined in 5248 Canadians aged 6 to 79 years based on survey data representing around 96% of the Canadian population. The study found that less than 1% of Canadians showed folate deficiencies and 40% showed high folate concentrations. Correction of folate deficiency and improved folate status, in part through fortification, has been associated with positive health outcomes such as the dramatic reduction in neural tube defects. Similar results have been seen in country's around the world, including the US.
Folic Acid During Pregnancy Goes Beyond Helping Neural Tube Defects
Children whose mothers were given iron and folic acid supplements during pregnancy were smarter, more organized and had better fine motor skills than children whose mothers did not get them, U.S. researchers said in a study appearing in the Journal of the American Medical Association. They had the opportunity to follow the offspring of women who had participated in a randomized trial of iron and folic acid and other micronutrients to assess neurocognitive function and outcomes. Prenatal iron and folic acid supplementation had a significant impact on the offspring's intellectual level and motor ability and ability during school age.
Folate as a Treatment for Depression
Lower serum folate levels appear to be associated with an increased risk for depressive symptoms, according to a study of large population-based, NHANES in Psychosomatic Medicine. According to researchers, the odds of having elevated depressive symptoms among individuals with the highest serum folate levels were about half that of those with the lowest levels. This is the first nationally representative study conducted among U.S. adults after mandatory fortification of food with folic acid that examines associations of serum folate with depressive symptoms. The only demographic where elevated homocysteine level was positively associated with elevated depressive symptoms was in adults 50 years and older. Folate, of course, is the main nutrient used to bring down homocysteine.
Future interventions to improve mental health outcomes among US adult should focus on increasing levels of serum folate say researchers. Clinicians should consider screening patients with depressive symptoms for serum folate and, if indicated, consider supplementation.
In a second study, a specific folate source for depression, L-methylfolate, is showing promise as an augmenting agent for depressed patients who are unresponsive to traditional antidepressants. Presented at the 2011 European Congress of Psychiatry, results revealed L-methylfolate, 15 mg/d, was effective, safe, and relatively well tolerated as an adjunct treatment strategy for patients with major depressive disorder (MDD) who were partial responders or nonresponders to selective serotonin reuptake inhibitor (SSRI) therapy. Folate deficiency is common in MDD. Roughly 70% of patients with MDD have a specific genetic factor that causes L-methylfolate deficiency. This folate metabolite dose should only be used in conjunction with a physician with specific expertise.
Unmetabolized (unabsorbed) Folate a Major Issue Not Just for The Depressed
Folate is a general term referring to folic acid and its reduced derivatives. Reduced, or activated folate is the coenzyme that participates in numerous methylation reactions, which include neurological biosynthesis. Importantly, methylation of chromatin and DNA by reduced folate is an important aspect of the maintenance of healthy gene expression.
Folic acid is a synthetic, oxidized folate that requires enzymatic reduction in order to function as a methyl donor. Reductive activation of folic acid is a multi-step process. Recent evidence indicates that the efficiency of this conversion may be low and variable, possibly explaining the high plasma levels of oxidized folic acid observed in subjects receiving supplemental folic acid. In food, folate naturally occurs primarily in the activated form, (L)-5-methyl-THF (5-MTHF). While synthetic folic acid can be converted to 5-MTHF in the body, this process requires the enzyme 5,10-methylene tetrahydrofolate reductase (MTHFR). Highly prevalent genetic variations in MTHFR compromise the efficiency of 5-MTHF synthesis in roughly 25% of the human population.
There are very few dietary supplements that can encompass folic acid and its two activated forms. Metagenics ActiFolate is one of them. It does not require modification and can therefore execute the beneficial effects of folate regardless of MTHFR genotype, efficiently absorbed and assimilated.
Another beneficial nutrient to support folate pathways is omega-3 fatty acids (EPA and DHA) in particular. An April Journal Nutrition study showed in those with impaired genetic folate pathways, subjects with the highest omega-3 intake had the lowest homocysteine levels and cardiovascular risk.
Folate Intake and Colorectal Cancer Risk
Experimental and observational studies have suggested that folate may play dual roles in colorectal cancer risk depending on the timing and dose. In this most recent study published in the American Journal of Clinical Nutrition, researchers examined the latency between folate intake and the incidence of colorectal cancer. Associations between folate intake were assessed every 2 to 4 years and risk of colorectal cancer and adenomas in the Nurses' Health Study was tracked for 24 years.
Long- and short-term intakes of total folate were associated with a lower risk of colorectal adenoma, with a strong association with intake 4–8 y before diagnosis. The current use of multivitamins for more than 15 years, but not a shorter duration of use, was associated with lower risk of colorectal cancer; and a shorter duration of use was related to lower risk of adenoma. Researchers did not observe an adverse effect of total folate or synthetic folic acid on risk of colorectal cancer or adenoma even during the folic acid fortification era.
No comments:
Post a Comment